SCHEDULE 13G/A: Farallon Capital Reports 9.99% Stake in Protagonist Therapeutics, Including Warrants
Beneficial Ownership Report
Farallon Capital and its affiliated entities have disclosed a significant beneficial ownership stake of 9.99% in Protagonist Therapeutics, Inc., comprising common shares and exercisable warrants as of December 31, 2024.
Summary
- Farallon Capital and its various affiliated funds and general partners, along with individual managing members, collectively reported beneficial ownership of 5,956,488 shares of Protagonist Therapeutics, Inc. common stock.
- This aggregate ownership represents 9.99% of the outstanding common stock of Protagonist Therapeutics, Inc.
- The reported stake includes 5,930,006 directly held common shares and 1,500,000 Common Stock Purchase Warrants.
- Due to a beneficial ownership limitation, only 26,482 of the 1,500,000 warrants were exercisable as of the reporting date, preventing the Reporting Persons from exceeding 9.99% ownership.
- The filing is an Amendment No. 7 to a Schedule 13G, indicating previous ownership disclosures by Farallon Capital regarding Protagonist Therapeutics.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements that would indicate a strong positive or negative sentiment. The presence of a significant institutional investor is generally neutral to slightly positive, but the beneficial ownership limitation on warrants introduces a minor constraint.
Positives
- The continued significant stake by Farallon Capital, a prominent investment firm, may signal confidence in Protagonist Therapeutics' long-term prospects.
- The holding of 1,500,000 warrants, even with current exercise limitations, indicates potential for increased ownership if the beneficial ownership cap is adjusted or if the total outstanding shares increase significantly.
Negatives
- The beneficial ownership limitation of 9.99% restricts Farallon Capital's immediate ability to fully exercise all warrants, potentially limiting their upside from the full warrant position.
Risks
- The beneficial ownership limitation on warrants means that a substantial portion of the warrants (1,473,518 out of 1,500,000) cannot be exercised if it would cause the Reporting Persons to exceed 9.99% ownership, potentially impacting their investment strategy or future influence.
Future Outlook
This Schedule 13G filing does not contain forward-looking statements or guidance regarding Protagonist Therapeutics' operational or financial performance. It solely reports beneficial ownership by Farallon Capital.
Industry Context
This filing reflects a significant institutional investment in a biotechnology company, common in the healthcare sector where specialized funds like Farallon Healthcare Partners Master, L.P. focus on high-growth potential firms. Such substantial stakes by major investment firms can be viewed as a vote of confidence in the company's market position and future prospects within the competitive biotech landscape.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member of Farallon General Partner and Manager of FCIP V General Partner, F5MI General Partner, and FHPM General Partner | NA | Patrick (Cheng) Luo | 01/01/2025 | Became a managing member/manager, leading to deemed beneficial ownership of shares held by Farallon Funds. |
Stakeholder Impact
- Shareholders: The disclosure of a large institutional stake by Farallon Capital provides transparency regarding a significant holder, which can influence market perception and trading activity.
- Company Management: Awareness of a major investor's stake and their potential influence on corporate decisions, especially given the 9.99% ownership threshold.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 01/01/2025 | Effective date for Patrick (Cheng) Luo becoming a managing member of Farallon General Partner and a manager of other Farallon GP entities. |
| 02/10/2025 | Date the Schedule 13G Amendment No. 7 was signed and filed. |
Keywords
Protagonist Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.